Kornimate/medical-research-clean huggingface dataset:
the soft tissue mobilization techniques on pms

Conditions: Premenstrual Syndrome; Premenstrual Pain; Chronic Pelvic Pain

Summary: the aim of this study is investigate the effects of progressive relaxation and myofascial release technique on blood flow velocity, pain, premenstrual symptoms and quality of life in premenstrual syndrome patients. there are tree groups in the study. these groups are; progressive muscle relaxation group, myofascial relaxation technique and control group. evaluations will be made by another physical therapist who is blinded to the groups. participants will be evaluated within the first 3 days of their menstrual cycle. baseline assessment and post- treatment assessment will be done. follow-up evaluation will be done on the fifth cycle, two cycles after the post-treatment evaluation.

the aim of this study is investigate the effects of progressive relaxation and myofascial release technique on blood flow velocity, pain, premenstrual symptoms and quality of life in premenstrual syndrome patients. the study planned as a single-blind randomized controlled trial. the volunteers who were invited to the study and signed the voluntary consent form will be randomized via random allocation software to divided into 3 groups. these groups are; progressive muscle relaxation group, myofascial relaxation technique and control group. evaluations will be made by another physical therapist who is blinded to the groups. participants will be evaluated within the first 3 days of their menstrual cycle. baseline assessment will be done in the first 3 days of the first cycle, after first treatment acute assessment will be done. post-treatment evaluation will be done in the first 3 days of the 3rd cycle after treatment for two cycles. follow-up evaluation will be done in the first 3 days of the fifth cycle, two cycles after the post-treatment evaluation.

Eligibility criteria:
inclusion criteria: * pain score of 4 cm or more according to the visual analogue scale. * having a regular menstrual cycle for 12 months (24-35 days). * according to the international physical activity questionnaire-short form (ipaq-sf), the weekly metabolic equivalent of task (met) value is below 600 met-min/week. exclusion criteria: * those who have undergone surgery in the last 6 months, * those who use cigarettes and alcohol, * those who are pregnant, * those with urinary, genital, gastrointestinal disorders, * those who have had hysterectomy surgery will be excluded.

Keywords: myofascial releasing technique progressive relaxation technique blood flow velocity
follow-up of myocardial t1 relaxation time in patients with anderson fabry disease

Conditions: Anderson-Fabry Disease

Summary: anderson fabry disease (afd) is an x-linked lysosomal storage disorder caused by a deficiency of the enzyme alpha-galactosidase. afd can involve various organs and lead to a series of clinical abnormalities. left ventricular hypertrophy in middle-aged men is one of its life threatening complications. it was shown that pending the absence of myocardial replacement fibrosis, substitution therapy could improve myocardial morphology and function as well as exercise capacity. today, there is no available marker of the efficacy of the treatment on the heart morphology and function. the t1 time (or longitudinal relaxation time) is one of the major components of the image formation in magnetic resonance imaging (along with t2 time and proton density). several techniques have been described to assess the myocardial t1-time. one of them called molli (modified look locker inversion recovery), was made available in research centres by the siemens company. in a study published in 2013, sado et al. showed in a series of various conditions (hypertension, afd, hypertrophic cardiomyopathy, al amyloidosis, aortic stenosis and healthy volunteers) that a septal t1 below a threshold of 940ms could discriminate afd patients. no overlap was shown with other conditions in this study. our experience with t1 mapping supports that finding (even though our threshold could be slightly different), and we could recently detect by mri a number of afd patients, some of them with hypertrophy, some others without hypertrophy. the effect of replagal® on the t1 relaxation time remains unknown. the purpose of that study was to follow-up the heart morphology, function and myocardial t1 relaxation time in a population of treated/untreated patients.


Eligibility criteria:
inclusion criteria: * patient with proven anderson fabry disease * patient with no agalsidase alpha (replagal®) treatment or * patient with agalsidase alpha (replagal®) treatment ongoing exclusion criteria: * pace maker / implantable cardiac defibrillator * claustrophobia * ocular foreign body * allergy to gadolinium chelates * pregnancy ongoing * age \< 18 years l

Keywords: enzyme replacement therapy
traumatic brain injury among homeless veterans

Conditions: Traumatic Brain Injury; Homelessness

Summary: objectives include: 1) establishing a psychometrically sound traumatic brain injury (tbi) screening measure for use among homeless veterans; 2) identifying the prevalence of those that screen positive for tbi among homeless veterans seeking va services; and 3) comparing psychiatric and psychosocial outcomes between those with and without a history of tbi.

short-term objectives include: 1. establishing the criterion-related validity of the traumatic brain injury-4 (tbi-4) questionnaire in the veteran homeless population using the ohio state university tbi-identification method (osu tbi-id) (corrigan et al., 2007) as the gold standard for establishing traumatic brain injury (tbi) diagnosis. 2. identifying the prevalence of those that screen positive for a lifetime history of tbi among homeless veterans. 3. comparing psychiatric outcomes (psychiatric hospitalizations, suicide attempts and deaths, and clinical contacts) and psychosocial outcomes between those with and without a lifetime history of tbi.

Eligibility criteria:
inclusion criteria: * at least 18 years of age, seeking homeless services at one of the va homeless services programs. exclusion criteria: * failure to provide informed consent, not older than 89 years of age.

Keywords: traumatic brain injury homelessness
the effect of pre-cesarean section guided imagery

Conditions: Cesarean Section

Summary: the aim of this study is to evaluate the effect of guided imagery applied before cesarean section on preoperative anxiety, fear and physiological parameters. the study will be carried out in two different groups. the practice will start with meeting the women 3 days before cesarean section. after the women are evaluated in terms of eligibility criteria for the research, the women who are eligible will be informed about the research and written informed consent will be obtained from the women who accept. the random distribution of women to the study groups will be carried out random. the following applications will be made to the groups.


Eligibility criteria:
inclusion criteria: * planned cesarean section * single birth * giving birth at term * no hearing problems * agreeing to participate in the research and obtaining written permission, exclusion criteria: * emergency cesarean section due to a health problem of the mother or baby * not completing the study
brassiere brow suture and internal browpexy

Conditions: Eyelid Diseases

Summary: brow ptosis is a common problem. internal browbexy and brassier suture are common surgical approach

upper eye transcutaneous blepharoplasty then combined browbexy and brassier suture are done

Eligibility criteria:
inclusion criteria: * brow ptosis and dermatochalasis exclusion criteria: * eyelid diseases and previous surgery

Keywords: blepharoplasty browbexy
a study of the pk and safety of single doses of sts101, dhe injection and nasal spray in healthy subjects

Conditions: Migraine; Migraine With Aura; Migraine Without Aura

Summary: single-center, single-dose, open-label, 5-period crossover (in each part), pharmacokinetic and safety study.

36 subjects received a single dose of sts101, 1.0 mg dhe mesylate im injection, and 2 mg dhe mesylate nasal spray in a randomized, 5-period crossover manner.

Eligibility criteria:
inclusion criteria: * 18 to 50 years of age at the time of enrollment. * signed the informed consent document. * subject judged to be healthy by a qualified physician exclusion criteria: * abnormal physical findings of clinical significance at the screening examination * significant abnormal laboratory values at the screening visit. * clinically significant symptoms or conditions that may have placed the subject at an unacceptable risk as a participant in the trial, or that may have interfered with the absorption, distribution, metabolism or excretion of the imp.

Keywords: dihydroergotamine dihydroergotamine mesylate migraine
a methadone maintenance treatment outcome study in three provinces in china

Conditions: HIV; Hepatitis C; Syphilis; Herpes Simplex Type II

Summary: the primary goal of this phe is to determine the effectiveness of a tailored education program for mmt service providers. it was to be evaluated through methadone dose levels prescribed to new patients after training completion. the effects of methadone dose, with and without the inclusion of additional counseling services, would be measured through mmt retention and illicit opioid use.

methadone treatment has became one of main actions taken in china to control the spread of hiv among drug users. however，the average methadone dose used is relatively low. an intensive methadone maintenance treatment (mmt) provider training on methadone dosage may be effective in increasing the methadone dose levels prescribed to new patients. the study will evaluate the effectiveness of a tailored education program for mmt service providers using subsequent methadone dose prescribed to new patients. the effects of methadone dose, with and without the inclusion of additional psychosocial services, will then be measured through mmt retention and illicit opioid use.

Eligibility criteria:
inclusion criteria: * client participants will include both men and women who are opiate-dependent drug users who started mmt not more than one month prior to enrollment in the study * 18 years of age or older * residing in the study areas

Keywords: idus high risk behaviors hiv mmt dosage and retention psychosocial services
a comparison of aerius continuous treatment versus aerius prn for chronic idiopathic urticaria (study p03147)

Conditions: Urticaria; Chronic Idiopathic Urticaria

Summary: this double-blind pilot study was conducted to establish the best way of using desloratadine treatment to protect quality of life of chronic idiopathic urticaria (ciu) patients, after an initial 4-weeks of daily treatment: prolonging systematic daily treatment or as needed (prn; in the case of symptoms).


Eligibility criteria:
inclusion criteria: * subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent. * subjects must be \>= 18 years of age * women of childbearing potential must have a negative urine pregnancy test at visit 1 (day 1) and must be using an acceptable method of birth control during the study. * subjects must be in general good health; ie, they must be free of any clinically significant disease (other than ciu) that would interfere with study evaluations. * subjects must understand and be able to adhere to visit schedules, and agree to complete the questionnaires and a diary. * subjects must have at least a 6-week history of ciu (pruritus and hives) prior to visit 1. exclusion criteria: * women who are pregnant or nursing. * subjects who used any investigational drug in the last 30 days prior to visit 1 * subjects with asthma requiring chronic use of inhaled or systemic corticosteroids. * subjects who have been treated with any investigational antibodies for asthma or allergic rhinitis in the 90 days prior to baseline. * subjects who have been treated with intra-muscular or intra-articular corticosteroids in the 90 days prior to baseline. * subjects with urticaria that is primarily due to physical urticaria or other known etiology, except dermographism. * subjects treated by immunosuppressive drugs. * subjects who have been hospitalized (including an emergency department visit) because of deterioration in their ciu within 3 months prior to visit 1. * subjects with a history of hypersensitivity to desloratadine or any of its excipients. * subjects previously randomized into this study. * subjects who have any clinically significant metabolic, cardiovascular, immunological, neurological, hematological, gastrointestinal, cerebrovascular, or respiratory disease, or any other disorder which, in the judgment of the investigator, may interfere with the study evaluations or affect subject safety. * subjects with a history of psychosis, antagonistic personality, poor motivation, hypochondriasis, or any other emotional or intellectual problems that are likely to limit the validity of consent to participate in the study. * subjects with a history of noncompliance with medications or treatment protocols.
characterization of familial myopathy and paget disease of bone

Conditions: Muscle Disorder; Bone Disorder

Summary: the researcher wants to explore the genetic causes of muscle disease. the researcher is particularly interested in muscle disorders that occur in combination with diseases of bone that appear to be passed on from generation to generation. diffuse optical spectroscopy will measure the concentrations of blood, water, and lipids (fats, for example) in your tissues. this device essentially measures the color of tissues in order to determine tissue physiology (its physical and chemical processes).

diffuse optical spectroscopy, the technique is fast and painless and was developed at the university of california, irvine. the diffuse optical spectroscopy instrument is actively involved in research studies, but is not yet a part of routine clinical practice. the result of this study will aid similar research projects that seek to improve our understanding of how tissues work and how alterations in metabolism affect long-term health. thediffuse optical spectroscopy measurement consists of placing a probe onto the surface of your body (calf, bicep, or head). this probe will be secured by either gentle hand pressure or fastened to your skin using clinically-approved wraps such as coban/wrap bandages or medical adhesive tape and medical glues. several dots will be made on your skin outlining the probe with a surgical felt tip marker. this is so we would be able to put the probe again on the same spot in case we needed to interrupt the measurement. the probe looks like a bar code scanner in a supermarket and it shines infrared light on your skin. there is no radiation involved with this light. in some cases where light signals are low, the optical detector will be placed directly onto your skin (but contained within an electronically shielded casing, and placed inside another plastic casing). (not offered during pregnancy).

Eligibility criteria:
inclusion criteria: male or female age 18 and older * diagnose of muscle or bone disorders * with a combination of medical problems including muscle and bone disease and their family members. exclusion criteria: * under 18 year of age * unrelated diagnosis

Keywords: muscle and bone disease
leveraging the emergency department to engage african american women in hiv pre-exposure prophylaxis

Conditions: HIV Infections

Summary: african american (aa) women are more vulnerable to hiv infection than other women. truvada, when used as pre-exposure prophylaxis (prep), is one of the most effective approaches for hiv prevention; however, prep use among aa women remains low and has not responded to traditional interventions. this study proposes for the first time an innovative computer-based motivational intervention, increasing prep uptake (iprep), which couples motivational messages woven into a traditional survey to raise awareness of risky sex and substance use behaviors.


Eligibility criteria:
inclusion criteria: * current hiv negative status (based on ed' hiv test outcome) * condomless sex in the last 3 months * substance use in the last 3 months * hiv testing during ed visit (usual care) * has a non-emergent health condition * has a working mobile device with them exclusion criteria: * ineligible for prep (see eligibility criteria to the right) * assigned male at birth * an hiv positive status * currently taking medication that are known contraindications for prep (brand name: truvada) * currently on prep

Keywords: african american women, hiv risk, substance use, sexual risk
to compare safety and the general imaging pattern of cyclotron produced technetium vs. generator produced technetium in patients with thyroid cancer

Conditions: Thyroid Neoplasms

Summary: the cyclotron production model of tc-99m pertechnetate (cpert) has received significant validation in the independent expert review conducted by natural resources canada (nrcan) in the follow up to the chalk river crisis. the university of alberta's edmonton pet centre and the edmonton radiopharmaceutical centre is a cyclotron / radiopharmacy unit, providing a safe, cost effective, unsubsidized, and reliable supply of radiopharmaceuticals to hospitals and clinics in edmonton and northern alberta. a phase i study is proposed to show safety of cpert as well as comparability with generator-produced tc-99m pertechnetate (gpert) in subjects with well differentiated thyroid carcinoma post-thyroidectomy and prior to planned i-131 iodide treatment.

patients who have had a thyroidectomy for cancer routinely have a tc-99m pertechnetate (gpert) scan at the cross cancer institute to check for thyroid tissue remnants prior to radioactive iodine therapy. the first 10 subjects will receive a cpert whole body scan, and and 20 subsequent case-matched controls (2 for each cpert subject, matched for age and gender) will receive a gpert whole body scan. cpert safety will be assessed by pre-injection and post-imaging collection of vital signs and blood samples (haematology and biochemistry). adverse event collection will be done for both cpert and gpert subjects. the whole body biodistribution pattern of cpert will be qualitatively compared to gpert by two independent and blinded nuclear medicine physicians.

Eligibility criteria:
inclusion criteria: * if female of child-bearing potential and outside of the window of 10 days since the first day of the last menstrual period, a negative pregnancy test is required. * have confirmed well differentiated thyroid cancer, post-thyroidectomy and pre-rai * biochemical parameters as measured are required to be within 5 times the normal limits for age * white blood cell count (wcb) \> 3.0/µl * absolute neutrophil count (anc) \> 1.5/µl * platelets \> 75,000/µl * hemoglobin \> 10 g/dl * able and willing to follow instructions and comply with the protocol * provide written informed consent prior to participation in the study * karnofsky performance scale score of 50 - 100 exclusion criteria: * nursing or pregnant females * biochemical parameters as measured outside 5 times the normal limits for age within 14 days of the pre-treatment scan * white blood cell count (wcb \< 3.0/µl) * absolute neutrophil count (anc) \< 1.5/µl * platelets \< 75,000/µl * haemoglobin \< 10 g/dl * unable and unwilling to follow instructions and comply with the protocol * unable or unwilling to provide written informed consent prior to participation in the study * karnofsky performance scale score \<50

Keywords: 99mtc pertechnetate thyroidectomy
safety, pharmacokinetics and pharmacodynamics of ta-7284 in type 2 diabetic patients

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of ta-7284 orally administered once daily for 15 days (1 day followed by a 1 day washout period and then 14 consecutive days). dose escalation design is utilized in this study, and dose escalation of ta-7284 will be starting with 25 mg (step 1). subsequent doses of 100 mg (step 2), 200 mg (step 3) and 400 mg (step 4) are planned after review of the tolerance and pk of the previous step.


Eligibility criteria:
inclusion criteria: * clinically stable type 2 diabetes mellitus * females without childbearing potential * body mass index (bmi) \>= 18.5 kg/m2 and \<= 39.9 kg/m2 * hemoglobin a1c levels \>= 6.5% and \<= 10% * fasting blood glucose levels \>= 140 mg/dl and \<= 270 mg/dl * systolic blood pressure \>= 95 mmhg and \ = 50 mmhg and \ = 50 bpm * patients who have not been administered anti-diabetic medication within 2 weeks prior to dosing * medicines if necessary for hypertension or dyslipidemia should be administered with stable dosage at least 3 months * treatment with diet and exercise should be unchanged for more than 3 months exclusion criteria: * type 1 diabetes mellitus or secondary diabetic mellitus * history of diabetic complications which need treatment * treatment with insulin, thiazolidinediones, thiazide diuretics、beta blockers or systemic steroids within 3 months prior to informed consent * serum creatinine \> upper limit of the normal range * patients with significant complications

Keywords: diabetes ta-7284
reducing fall risk post hip fracture in mild cognitive impairment

Conditions: Hip Fractures; Mild Cognitive Impairment

Summary: hip fracture is recognized as one of the most serious consequences of osteoporosis, less than half regain pre-fracture independence. 95% of all hip fractures in older adults are due to falls. thus, reducing fall risk while restoring function post-hip fracture is critical. many with fall-related hip fractures have cognitive impairment; cognitive impairment increases the risk of falls. the purpose of this 6-month proof-of-concept randomized controlled trial (rct) is to assess the efficacy of the home-based otago exercise program (oep) compared with usual care in reducing fall risk among older adults with mild cognitive impairment (mci) and a fall-related hip fracture.

hip fracture is recognized as one of the most serious consequences of osteoporosis, less than half regain pre-fracture independence. 95% of all hip fractures in older adults are due to falls. thus, reducing fall risk while restoring function post-hip fracture is critical. many with fall-related hip fractures have cognitive impairment and they are less likely to regain pre-fracture level of function than those without cognitive impairment. cognitive impairment also increase falls risk. it is currently unknown whether exercise is efficacious in reducing fall risk and promoting function among older adults with mild cognitive impairment (mci) and a fall-related hip fracture. the purpose of this 6-month proof-of-concept rct is to assess the efficacy of the home-based otago exercise program (oep) compared with usual care in reducing fall risk among community-dwelling older adults with mci and a fall-related hip fracture.

Eligibility criteria:
inclusion criteria: 1) aged 65 or older; 2) sustained a fall-related hip fracture in the last 12 months and have returned home; 3) have preserved general cognition as indicated by a mini-mental state examination (mmse) score = or \> 20/30; 4) have subjective memory complaints, determined by interview;22 5) score \ 3 months) on a fixed dose of anti-dementia medications (e.g., donepezil, galantamine) during the rct; 8) are expected to live \> 12 months (based on the geriatricians' expert opinion); 9) can read, write, and speak english with acceptable visual and auditory acuity; 10) are able to walk 3 meters with or without an assistive device; and 1) provide written informed consent. exclusion criteria: 1) diagnosed with or suspected to have (by the geriatrician) a neurodegenerative disease (e.g., parkinson's disease) or dementia; 2) had a clinical stroke; or 3) have a history indicative of carotid sinus sensitivity (i.e., syncopal falls).

Keywords: mobility exercise fall risk